Bristol Myers Squibb (BMY) Income towards Parent Company (2009 - 2026)
Bristol Myers Squibb's (BMY) quarterly Income towards Parent Company came in at $3.3 billion in Q2 2026, up 152.55% year-over-year from $1.3 billion in Q2 2025, and up 23.78% quarter-over-quarter from $2.7 billion in Q1 2026.
Analysis
Bristol Myers Squibb (BMY) Income towards Parent Company (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Income towards Parent Company for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income towards Parent Company rose 152.55% year-over-year to $3.3 billion in Q2 2026; TTM through Jun 2026 was $9.3 billion, a 83.1% increase from a year earlier, with the FY2025 full-year figure at $7.1 billion, up 178.99% from the prior year.
- Income towards Parent Company was $3.3 billion for Q2 2026 at Bristol Myers Squibb, up from $2.7 billion in the prior quarter.
- Over five years, Income towards Parent Company peaked at $3.3 billion in Q2 2026 and troughed at -$11.9 billion in Q1 2024.
- A 5-year average of $1.0 billion and a median of $1.7 billion in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 625.28% in 2024 and surged 1328.95% in 2025, its largest moves.
- Over 5 years, Income towards Parent Company stood at $2.0 billion in 2022, then slipped by 12.99% to $1.8 billion in 2023, then slumped by 95.69% to $76.0 million in 2024, then surged by 1328.95% to $1.1 billion in 2025, then soared by 205.34% to $3.3 billion in 2026.
- The last three Income towards Parent Company figures came in at $3.3 billion (Q2 2026), $2.7 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.32 Bn |
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Mar 31, 2024 | -11.91 Bn |
| Dec 31, 2023 | 1.76 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.28 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 1.55 Bn |